ea0049gp177 | Pituitary | ECE2017
Ferone Diego
, Borson-Chazot Francoise
, Cailleux Anne
, Horsch Dieter
, lahner Harald
, Pivonello Rosario
, Tauchmanova Libuse
, Darstein Christelle
, Olsson Hakan
, Tiberg Fredrik
, Pavel Marianne
Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...